{"_id":"5e7af01eb2924f373d23e497","modifiedBy":{"annotator":{"5e6fffcfb2924f373d23e464":"Curator3@molecularconnections.com"}},"metadata":{"articleTitle":"Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study","journal":"","manuscriptId":"","submittingAuthor":"","submittingAuthoremail":"","authors":["Petkov ValentinaI","Miller DaveP","Howlader Nadia","Gliner Nathan","Howe Will","Schussler Nicola","Cronin Kathleen","Baehner FrederickL","Cress Rosemary","Deapen Dennis","Glaser SallyL","Hernandez BrendaY","Lynch CharlesF","Mueller Lloyd","Schwartz AnnG","Schwartz StephenM","Stroup Antoinette","Sweeney Carol","Tucker ThomasC","Ward KevinC","Wiggins Charles","Wu Xiao-Cheng","Penberthy Lynne","Shak Steven"],"funders":"No special funders","institutions":[],"doi":"","pmid":""},"datasets":{"deleted":[],"extracted":{"dataset-1":{"id":"dataset-1","cert":"0.9652548432350159","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Five-year estimates of overall survival and non-breast-cancerspecific mortality (non-BCSM) were also determined.","status":"saved"},"dataset-2":{"id":"dataset-2","cert":"0.9801158905029297","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Secondary survival analyses of various subgroups included patients of all ages and patients with node-positive disease.","status":"saved"},"dataset-3":{"id":"dataset-3","cert":"0.33528584241867065","dataType":"genetic data","subType":"","description":"","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Patients were considered HR+ if their tumors were estrogen receptor-or progesterone receptor-positive (ER+ or PR+) by the SEER-reported ER and PR immunohistochemistry results (borderline results were considered positive) and by the 21-gene assay quantitative reverse transcription-PCR (RT-PCR) single-gene ER or PR results.","status":"saved"},"dataset-4":{"id":"dataset-4","cert":"0.7117895483970642","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Patients were considered node-negative or node-positive based on the data collected by SEER.","status":"saved"},"dataset-5":{"id":"dataset-5","cert":"0.9677854180335999","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Both male and female patients were included in all analyses.","status":"saved"},"dataset-6":{"id":"dataset-6","cert":"0.9685858488082886","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Underlying causes of death (CODs) were ascertained by the SEER registries through linkages with state death certificates and the National Death Index from the National Center for Health Statistics.","status":"saved"},"dataset-7":{"id":"dataset-7","cert":"0.9669367074966431","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"The continuous Recurrence Score result (0-100) was evaluated in secondary analyses.","status":"saved"},"dataset-8":{"id":"dataset-8","cert":"0.9654628038406372","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Proportional hazards assumptions were assessed and met in the final models.","status":"saved"},"dataset-9":{"id":"dataset-9","cert":"0.8369592428207397","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Subgroup analyses were conducted by age, race, tumor size, tumor grade, and SES Index.","status":"saved"}},"current":{"dataset-1":{"id":"dataset-1","cert":"0.9652548432350159","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Five-year estimates of overall survival and non-breast-cancerspecific mortality (non-BCSM) were also determined.","status":"saved"},"dataset-2":{"id":"dataset-2","cert":"0.9801158905029297","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Secondary survival analyses of various subgroups included patients of all ages and patients with node-positive disease.","status":"saved"},"dataset-3":{"id":"dataset-3","cert":"0.33528584241867065","dataType":"genetic data","subType":"","description":"","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Patients were considered HR+ if their tumors were estrogen receptor-or progesterone receptor-positive (ER+ or PR+) by the SEER-reported ER and PR immunohistochemistry results (borderline results were considered positive) and by the 21-gene assay quantitative reverse transcription-PCR (RT-PCR) single-gene ER or PR results.","status":"saved"},"dataset-4":{"id":"dataset-4","cert":"0.7117895483970642","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Patients were considered node-negative or node-positive based on the data collected by SEER.","status":"saved"},"dataset-5":{"id":"dataset-5","cert":"0.9677854180335999","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Both male and female patients were included in all analyses.","status":"saved"},"dataset-6":{"id":"dataset-6","cert":"0.9685858488082886","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Underlying causes of death (CODs) were ascertained by the SEER registries through linkages with state death certificates and the National Death Index from the National Center for Health Statistics.","status":"saved"},"dataset-7":{"id":"dataset-7","cert":"0.9669367074966431","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"The continuous Recurrence Score result (0-100) was evaluated in secondary analyses.","status":"saved"},"dataset-8":{"id":"dataset-8","cert":"0.9654628038406372","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Proportional hazards assumptions were assessed and met in the final models.","status":"saved"},"dataset-9":{"id":"dataset-9","cert":"0.8369592428207397","dataType":"tabular data","subType":"","description":"Tabular data consist of a table with rows and columns. Each cell of the table contains numbers or text. A sample table contains data about one or more entities gathered during a research project. These entities might be biological organisms, soil samples, ceramic dishes, or human organs.","bestDataFormatForSharing":"","mostSuitableRepositories":"","DOI":"","name":"","comments":"","text":"Subgroup analyses were conducted by age, race, tumor size, tumor grade, and SES Index.","status":"saved"}}},"status":"datasets","source":"\u003c?xml version=\"1.0\" encoding=\"UTF-8\"?\u003e\u003cTEI xmlns=\"http://www.tei-c.org/ns/1.0\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xml:space=\"preserve\" xsi:schemaLocation=\"http://www.tei-c.org/ns/1.0 /home/lopez/grobid/dataseer-ml/../grobid-home/schemas/xsd/Grobid.xsd\"\u003e\u003cteiHeader xml:lang=\"en\"\u003e\u003cfileDesc\u003e\u003ctitleStmt\u003e\u003ctitle level=\"a\" type=\"main\"\u003eBreast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study\u003c/title\u003e\u003c/titleStmt\u003e\u003cpublicationStmt\u003e\u003cpublisher/\u003e\u003cavailability status=\"unknown\"\u003e\u003clicence/\u003e\u003c/availability\u003e\u003cdate type=\"published\" when=\"2016\"\u003e2016. 16017\u003c/date\u003e\u003c/publicationStmt\u003e\u003csourceDesc\u003e\u003cbiblStruct\u003e\u003canalytic\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eValentina\u003c/forename\u003e\u003cforename type=\"middle\"\u003eI\u003c/forename\u003e\u003csurname\u003ePetkov\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eDave\u003c/forename\u003e\u003cforename type=\"middle\"\u003eP\u003c/forename\u003e\u003csurname\u003eMiller\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eNadia\u003c/forename\u003e\u003csurname\u003eHowlader\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eNathan\u003c/forename\u003e\u003csurname\u003eGliner\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eWill\u003c/forename\u003e\u003csurname\u003eHowe\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eNicola\u003c/forename\u003e\u003csurname\u003eSchussler\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eKathleen\u003c/forename\u003e\u003csurname\u003eCronin\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eFrederick\u003c/forename\u003e\u003cforename type=\"middle\"\u003eL\u003c/forename\u003e\u003csurname\u003eBaehner\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eRosemary\u003c/forename\u003e\u003csurname\u003eCress\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eDennis\u003c/forename\u003e\u003csurname\u003eDeapen\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eSally\u003c/forename\u003e\u003cforename type=\"middle\"\u003eL\u003c/forename\u003e\u003csurname\u003eGlaser\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eBrenda\u003c/forename\u003e\u003cforename type=\"middle\"\u003eY\u003c/forename\u003e\u003csurname\u003eHernandez\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eCharles\u003c/forename\u003e\u003cforename type=\"middle\"\u003eF\u003c/forename\u003e\u003csurname\u003eLynch\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eLloyd\u003c/forename\u003e\u003csurname\u003eMueller\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eAnn\u003c/forename\u003e\u003cforename type=\"middle\"\u003eG\u003c/forename\u003e\u003csurname\u003eSchwartz\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eStephen\u003c/forename\u003e\u003cforename type=\"middle\"\u003eM\u003c/forename\u003e\u003csurname\u003eSchwartz\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eAntoinette\u003c/forename\u003e\u003csurname\u003eStroup\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eCarol\u003c/forename\u003e\u003csurname\u003eSweeney\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eThomas\u003c/forename\u003e\u003cforename type=\"middle\"\u003eC\u003c/forename\u003e\u003csurname\u003eTucker\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eKevin\u003c/forename\u003e\u003cforename type=\"middle\"\u003eC\u003c/forename\u003e\u003csurname\u003eWard\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eCharles\u003c/forename\u003e\u003csurname\u003eWiggins\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eXiao-Cheng\u003c/forename\u003e\u003csurname\u003eWu\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eLynne\u003c/forename\u003e\u003csurname\u003ePenberthy\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eSteven\u003c/forename\u003e\u003csurname\u003eShak\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003ctitle level=\"a\" type=\"main\"\u003eBreast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study\u003c/title\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\" type=\"main\"\u003enpj Breast Cancer\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e2\u003c/biblScope\u003e\u003cdate type=\"published\" when=\"2016\"\u003e2016. 16017\u003c/date\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003cidno type=\"DOI\"\u003e10.1038/npjbcancer.2016.17\u003c/idno\u003e\u003cnote\u003eARTICLE OPEN\u003c/note\u003e\u003c/biblStruct\u003e\u003c/sourceDesc\u003e\u003c/fileDesc\u003e\u003cencodingDesc\u003e\u003cappInfo\u003e\u003capplication ident=\"GROBID-SDO\" version=\"0.6.0-SNAPSHOT\" when=\"2020-03-25T05:45+0000\"\u003e\u003cdesc\u003eGROBID - A machine learning software for extracting information from scholarly documents\u003c/desc\u003e\u003cref target=\"https://github.com/kermitt2/grobid-sdo\"/\u003e\u003c/application\u003e\u003c/appInfo\u003e\u003c/encodingDesc\u003e\u003cprofileDesc\u003e\u003cabstract\u003e\u003cdiv\u003e\u003cp\u003e\u003cs\u003eThe 21-gene Recurrence Score assay is validated to predict recurrence risk and chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer.\u003c/s\u003e\u003cs\u003eTo determine prospective breast-cancer-specific mortality (BCSM) outcomes by baseline Recurrence Score results and clinical covariates, the National Cancer Institute collaborated with Genomic Health and 14 population-based registries in the the Surveillance, Epidemiology, and End Results (SEER) Program to electronically supplement cancer surveillance data with Recurrence Score results.\u003c/s\u003e\u003cs\u003eThe prespecified primary analysis cohort was 40-84 years of age, and had node-negative, HR+, HER2-negative, nonmetastatic disease diagnosed between January 2004 and December 2011 in the entire SEER population, and Recurrence Score results (N = 38,568).\u003c/s\u003e\u003cs\u003eUnadjusted 5-year BCSM were 0.4% (n = 21,023; 95% confidence interval (CI), 0.3-0.6%),\u003c/s\u003e\u003cs\u003e1.4% (n = 14,494; 95% CI, 1.1-1.7%),\u003c/s\u003e\u003cs\u003eand 4.4% (n = 3,051; 95% CI, 3.4-5.6%)\u003c/s\u003e\u003cs\u003efor Recurrence Score o 18, 18-30, and \u0026#x2A7E; 31 groups, respectively (P o0.001).\u003c/s\u003e\u003cs\u003eIn multivariable analysis adjusted for age, tumor size, grade, and race, the Recurrence Score result predicted BCSM (P o 0.001).\u003c/s\u003e\u003cs\u003eAmong patients with node-positive disease (micrometastases and up to three positive nodes; N = 4,691), 5-year BCSM (unadjusted) was 1.0% (n = 2,694; 95% CI, 0.5-2.0%),\u003c/s\u003e\u003cs\u003e2.3% (n = 1,669; 95% CI, 1.3-4.1%),\u003c/s\u003e\u003cs\u003eand 14.3% (n = 328; 95% CI, 8.4-23.8%)\u003c/s\u003e\u003cs\u003efor Recurrence Score o 18, 18-30, \u0026#x2A7E; 31 groups, respectively (P o0.001).\u003c/s\u003e\u003cs\u003eFive-year BCSM by Recurrence Score group are reported for important patient subgroups, including age, race, tumor size, grade, and socioeconomic status.\u003c/s\u003e\u003cs\u003eThis SEER study represents the largest report of prospective BCSM outcomes based on Recurrence Score results for patients with HR+, HER2negative, node-negative, or node-positive breast cancer, including subgroups often under-represented in clinical trials.\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003c/abstract\u003e\u003c/profileDesc\u003e\u003c/teiHeader\u003e\u003ctext xml:lang=\"en\"\u003e\u003cbody\u003e\u003cdiv\u003e\u003chead\u003eINTRODUCTION\u003c/head\u003e\u003cp\u003e\u003cs\u003eDespite unprecedented advances in breast cancer diagnosis and treatment, health-care quality and outcomes remain variable, with significant disparities associated with many factors, such as age and race, and the location of care.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b0\" type=\"bibr\"\u003e[1]\u003c/ref\u003e \u003cref target=\"#b1\" type=\"bibr\"\u003e[2]\u003c/ref\u003e \u003cref target=\"#b2\" type=\"bibr\"\u003e[3]\u003c/ref\u003e \u003cref target=\"#b3\" type=\"bibr\"\u003e[4]\u003c/ref\u003e Leading organizations, including the Institute of Medicine, \u003cref target=\"#b4\" type=\"bibr\"\u003e5\u003c/ref\u003e the American Society of Clinical Oncology, \u003cref target=\"#b5\" type=\"bibr\"\u003e6,\u003c/ref\u003e \u003cref type=\"bibr\"\u003e7\u003c/ref\u003e and the European Organisation for Research and Treatment of Cancer, \u003cref target=\"#b6\" type=\"bibr\"\u003e8\u003c/ref\u003e have emphasized the need for new research models to more precisely identify what works in clinical practice and encourage appropriate value-based cancer treatment.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eIn recent years, technologies such as multigene expression analysis, next-generation sequencing, and liquid biopsy, have raised the potential to define appropriate patient subgroups for more precise cost-effective care and improved health outcomes.\u003c/s\u003e\u003cs\u003eThe 21-gene assay has been clinically validated in \u0026apos;prospectiveretrospective\u0026apos; studies on archival tumor tissue to provide both prognostic and predictive information for chemotherapy benefit in early stage, hormone-receptor-positive (HR+), node-negative, or node-positive breast cancer.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b7\" type=\"bibr\"\u003e[9]\u003c/ref\u003e \u003cref target=\"#b8\" type=\"bibr\"\u003e[10]\u003c/ref\u003e \u003cref target=\"#b9\" type=\"bibr\"\u003e[11]\u003c/ref\u003e \u003cref target=\"#b10\" type=\"bibr\"\u003e[12]\u003c/ref\u003e Recently, the first results from the Trial Assigning Individualized Options for Treatment (TAILORx), a multi-center, prospectively conducted trial of 10,253 women with early-stage breast cancer, were reported.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b11\" type=\"bibr\"\u003e13\u003c/ref\u003e For the 1,626 trial participants with Recurrence Score results o 11 (TAILORx lowrange stratum) who received hormonal therapy alone without chemotherapy, 5-year freedom from distant recurrence was 99.3% (95% confidence interval (CI), 98.7-99.6%).\u003c/s\u003e\u003cs\u003eThese findings demonstrate that patients with low Recurrence Score results can be effectively spared from adjuvant chemotherapy.\u003c/s\u003e\u003cs\u003eResults from two other recent studies provide additional evidence of excellent outcomes for patients treated with hormonal therapy alone based on low Recurrence Score results.\u003c/s\u003e\u003cs\u003eIn the Clalit Health Services study, patients with node-negative or micrometastatic disease and Recurrence Score results o18 (standard low-range group), nearly all of whom (98%) were treated with hormonal therapy without chemotherapy, had o 1% risk of distant recurrence and 0% risk of breast-cancer-specific mortality (BCSM) at 5 years.\u003c/s\u003e\u003cs\u003e14 In the prospective PlanB trial, patients with 0-3 positive lymph nodes and Recurrence Score results \u0026#x2A7D; 11, who were treated with hormonal therapy alone, had 3-year relapse-free survival exceeding 98%.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b13\" type=\"bibr\"\u003e15\u003c/ref\u003e As we await results of the TAILORx mid-range stratum (Recurrence Score results \u003cref target=\"#b9\" type=\"bibr\"\u003e[11]\u003c/ref\u003e \u003cref target=\"#b10\" type=\"bibr\"\u003e[12]\u003c/ref\u003e \u003cref target=\"#b11\" type=\"bibr\"\u003e[13]\u003c/ref\u003e \u003cref target=\"#b12\" type=\"bibr\"\u003e[14]\u003c/ref\u003e \u003cref target=\"#b13\" type=\"bibr\"\u003e[15]\u003c/ref\u003e \u003cref target=\"#b14\" type=\"bibr\"\u003e[16]\u003c/ref\u003e \u003cref target=\"#b15\" type=\"bibr\"\u003e[17]\u003c/ref\u003e \u003cref target=\"#b16\" type=\"bibr\"\u003e[18]\u003c/ref\u003e \u003cref target=\"#b17\" type=\"bibr\"\u003e[19]\u003c/ref\u003e \u003cref target=\"#b18\" type=\"bibr\"\u003e[20]\u003c/ref\u003e \u003cref target=\"#b19\" type=\"bibr\"\u003e[21]\u003c/ref\u003e \u003cref type=\"bibr\"\u003e[22]\u003c/ref\u003e \u003cref target=\"#b20\" type=\"bibr\"\u003e[23]\u003c/ref\u003e \u003cref target=\"#b21\" type=\"bibr\"\u003e[24]\u003c/ref\u003e \u003cref target=\"#b22\" type=\"bibr\"\u003e[25]\u003c/ref\u003e , it would be desirable to have additional evidence of the utility of the 21-gene assay in patients with Recurrence Score result o 18, the standard cutoff used in contemporary clinical practice for selection of hormone therapy alone.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eInitiated in 1973, the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute is an authoritative population-based cancer surveillance program, covering~30% of the US population and capturing over 98% of incident cancer cases in these covered regions.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b14\" type=\"bibr\"\u003e16\u003c/ref\u003e SEER Program registries collect standardized patient information on demographics, primary tumor site, and characteristics (histology, grade, stage, and so on), first course of treatment, and survival (survival time, vital status, and cause of death), as mandated by respective state laws.\u003c/s\u003e\u003cs\u003eSEER has required the collection of breast cancer multigene test results for cases diagnosed with breast cancer in 2010 and after.\u003c/s\u003e\u003cs\u003eTo supplement registry data with more complete and accurate multigene test results, we electronically linked Recurrence Score results from the Genomic Health Clinical Laboratory database with each of the SEER registries.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eIn this first report, we determined the relationship between Recurrence Score results and prospective BCSM for the large population in the SEER program with node-negative and nodepositive breast cancer, including subgroups (e.g., racial minorities, the elderly, and the young) that are often under-represented in clinical trials.\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003chead\u003eRESULTS\u003c/head\u003e\u003c/div\u003e\u003cdiv subtype=\"dataseer\"\u003e\u003chead\u003ePopulation\u003c/head\u003e\u003cp\u003e\u003cs\u003eA total of 379,103 patients were newly diagnosed with primary invasive breast cancer between 2004 and 2011 in the participating SEER registries \u003cref target=\"#tab_0\" type=\"table\"\u003e(Table 1\u003c/ref\u003e ; Supplementary \u003cref target=\"#fig_0\" type=\"figure\"\u003eFigure S1\u003c/ref\u003e ).\u003c/s\u003e\u003cs\u003eThese patients resided in 12 individual SEER states: California (3 registries, 41%), New Jersey (12%), Georgia (11%), Washington (13 Puget Sound region counties only, 6%), Connecticut (5%), Kentucky (5%), Louisiana (5%), Michigan (metropolitan Detroit counties only, 5%), Iowa (4%), Hawaii (2%), New Mexico (2%), and Utah (2%).\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eOf 379,103 patients, 45,287 (12%) had HR+, nonmetastatic disease and Recurrence Score results, including 40,134 with nodenegative disease, 4,691 with micrometastates or up to three positive nodes (N+(mic,1-3)), and 462 with four or more positive nodes or unknown/missing nodal status.\u003c/s\u003e\u003cs\u003eNearly all patients (99.5%) who had 21-gene assay testing had fewer than four positive lymph nodes.\u003c/s\u003e\u003cs\u003eOnly 165 of 16,202 patients with 4-9 positive nodes and 41 of 7,320 patients with 10 or more positive nodes had testing.\u003c/s\u003e\u003cs\u003eDemographic characteristics of tested and untested patients of all ages diagnosed between 2004 and 2011 with node-negative or node-positive (N+(mic,1-3)) are shown in \u003cref target=\"#tab_0\" type=\"table\"\u003eTable 1\u003c/ref\u003e .\u003c/s\u003e\u003cs\u003eMedian follow-up of patients with node-negative disease was longer than that of patients with node-positive (N+(mic,1-3)) disease (39 months versus 30 months), reflecting later adoption of the test for use in patients with node-positive disease.\u003c/s\u003e\u003cs\u003eA total of 38,568 patients (10%) were eligible for the prespecified primary analysis (had HR+, HER2-negative, nodenegative, nonmetastatic disease; had Recurrence Score results; and were 40-84 years of age; Supplementary \u003cref target=\"#fig_0\" type=\"figure\"\u003eFigure S1\u003c/ref\u003e ).\u003c/s\u003e\u003cs\u003eMedian age of the prespecified primary analysis cohort was 57 years; 99.4% were female; 84% were white, 29% and 54% had tumors of histologic grade 1 and grade 2, respectively; 25% and 53% had tumors of \u0026#x2A7D; 1 cm and 41 to 2 cm in size, respectively.\u003c/s\u003e\u003cs\u003eMedian follow-up for the primary analysis cohort was 39 months; 8,239 (21%) patients had 45 years of follow-up.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eRecurrence Score result and breast-cancer-specific mortality (Node-negative) Of 38,568 patients in the prespecified primary analysis cohort, 21,023 (55%) had Recurrence Score results o18, 14,494 (38%) had results 18-30, and 3,051 (8%) had results \u0026#x2A7E; 31.\u003c/s\u003e\u003cs\u003eBCSM was significantly associated with Recurrence Score results (P o 0.001) ( \u003cref target=\"#fig_0\" type=\"figure\"\u003eFigure 1\u003c/ref\u003e ).\u003c/s\u003e\u003cs\u003eUnadjusted 5-year estimates of BCSM were 0.4% (95% CI, 0.3-0.6%),\u003c/s\u003e\u003cs\u003e1.4% (95% CI, 1.1-1.7%),\u003c/s\u003e\u003cs\u003eand 4.4% (95% CI, 3.4-5.6%)\u003c/s\u003e\u003cs\u003efor patients Recurrence Score results o 18, 18-30, and \u0026#x2A7E; 31, respectively.\u003c/s\u003e\u003cs\u003eChemotherapy use was reported as \u0026apos;yes\u0026apos; in 7%, 34%, and 69% of patients in the Recurrence Score o18, 18-30, and \u0026#x2A7E; 31 groups, respectively (the remaining patients in each group were reported in SEER as \u0026apos;no/unknown chemotherapy use\u0026apos;).\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs cert=\"0.9652548432350159\" id=\"dataset-1\" type=\"tabular data\"\u003eFive-year estimates of overall survival and non-breast-cancerspecific mortality (non-BCSM) were also determined.\u003c/s\u003e\u003cs\u003eThere was a significant difference in overall survival among Recurrence Score groups (P o 0.001), with earlier mortality corresponding to Recurrence Score results \u0026#x2A7E; 31 (data not shown).\u003c/s\u003e\u003cs\u003eThere was no significant difference in non-BCSM among Recurrence Score groups (P = 0.10).\u003c/s\u003e\u003cs\u003eFive-year other-cause mortality for the primary analysis cohort overall was 5.1% (95% CI, 4.8-5.4%),\u003c/s\u003e\u003cs\u003eand 5.1% (95%CI, 4.7-5.6%),\u003c/s\u003e\u003cs\u003e5.0% (95%CI, 4.5-5.5%),\u003c/s\u003e\u003cs\u003eand 5.6% (95%CI, 4.6-6.9%)\u003c/s\u003e\u003cs\u003efor Recurrence Score o 18, 18-30, and \u0026#x2A7E; 31 groups, respectively.\u003c/s\u003e\u003cs\u003eAge was the strongest predictor of non-BCSM (P o 0.001).\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eRecurrence Score result and breast-cancer-specific mortality (Node-positive) A total of 4,691 patients with positive lymph nodes (N+(mic,1-3)) had Recurrence Score results (Supplementary \u003cref target=\"#fig_0\" type=\"figure\"\u003eFigure S1\u003c/ref\u003e ).\u003c/s\u003e\u003cs\u003eOf these, 2,694 (57%) had Recurrence Score results o18, 1,669 (36%) had results 18-30, and 328 (7%) had results \u0026#x2A7E; 31.\u003c/s\u003e\u003cs\u003eIn addition, 50% of these patients had tumors 410 to 20 mm in size, 55% had moderate grade tumors, and 78.3% were 50 years of age or older ( \u003cref target=\"#tab_0\" type=\"table\"\u003eTable 1)\u003c/ref\u003e .\u003c/s\u003e\u003cs\u003eAmong patients with node-positive (N+(mic,1-3)) disease, 5-year BCSM was significantly different for the three Recurrence Score groups: 1.0% (95% CI, 0.5-2.0%) in the o 18 group, 2.3% (95% CI, 1.3-4.1%) in the 18-30 group, and 14.3% (95% CI, 8.4-23.8%) in the \u0026#x2A7E; 31 group (P o 0.001).\u003c/s\u003e\u003cs\u003eChemotherapy use was reported as \u0026apos;yes\u0026apos; (rather than \u0026apos;no/unknown\u0026apos;) in 23%, 47%, and 75% of patients in the Recurrence Score o18, 18-30, and \u0026#x2A7E; 31 groups, respectively.\u003c/s\u003e\u003cs\u003eExcluding patients with micrometastatic disease, there were 2,617 patients with 1-3 positive nodes.\u003c/s\u003e\u003cs\u003eOf these, 1,487 also had Recurrence Score results o 18 with 5-year BCSM of 1.3% (95% CI, 0.6-2.9%).\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eSubgroups and breast-cancer-specific mortality Recurrence Score group was significantly prognostic (P \u0026#x2A7D; 0.001) for 5-year BCSM for the node-negative and the node-positive (N+(mic,1-3)) populations as wholes, in every node-negative subgroup of age, grade, race, and socioeconomic (SES) status, and in the node-positive (N+(mic,1-3)) subgroups with substantial numbers of patients (410 to 20 mm, moderate grade, age 60-69 years, and White; \u003cref target=\"#fig_1\" type=\"figure\"\u003eFigure 2a\u003c/ref\u003e -j \u003cref target=\"#tab_0\" type=\"table\"\u003eSupplementary Table S1\u003c/ref\u003e ).\u003c/s\u003e\u003cs\u003eNotably, 5-year BCSM was 1.3% or lower for patients with Recurrence Score results o 18, regardless of nodal status and age group.\u003c/s\u003e\u003cs\u003eSimilarly, low BCSM was observed for patients o 70 years of age with Recurrence Score results 18-30.\u003c/s\u003e\u003cs\u003eHowever, for patients with Recurrence Score results \u0026#x2A7E; 31, 5-year BCSM was substantially higher and ranged from 2.0 to 21.6%, depending on age group \u003cref target=\"#fig_1\" type=\"figure\"\u003e(Figure 2a\u003c/ref\u003e ).\u003c/s\u003e\u003cs\u003eAmong patients with node-positive (N+(mic,1-3)) disease, those with Recurrence Score results \u0026#x2A7E; 31 had 5-year BCSM that exceeded 9.5%, regardless of age group \u003cref target=\"#fig_1\" type=\"figure\"\u003e(Figure 2b\u003c/ref\u003e ).\u003c/s\u003e\u003cs\u003eFor patients with both node-negative and node-positive (N+(mic,1-3)) disease, reported chemotherapy use generally decreased with increasing age.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eFor patients with node-negative or node-positive (N+(mic,1-3)) disease, those with higher Recurrence Score results had higher 5-year BCSM than those with lower results, regardless of race (White or Black; \u003cref target=\"#fig_1\" type=\"figure\"\u003eFigure 2c\u003c/ref\u003e ,d) and regardless of SES quintile \u003cref target=\"#fig_1\" type=\"figure\"\u003e(Figure 2e\u003c/ref\u003e ,f).\u003c/s\u003e\u003cs\u003eOf note, among patients with node-negative disease and Recurrence Score results \u0026#x2A7E; 31, 5-year BCSM appeared to decrease with higher quintiles, despite similar reported chemotherapy use across SES quintiles (68-70%; \u003cref target=\"#fig_1\" type=\"figure\"\u003eFigure 2e\u003c/ref\u003e ).\u003c/s\u003e\u003cs\u003eAmong patients with node-positive (N+(mic,1-3)) disease and Recurrence Score results \u0026#x2A7E; 31, 5-year BCSM exceeded 9%, regardless of SES quintile ( \u003cref target=\"#fig_1\" type=\"figure\"\u003eFigure 2f\u003c/ref\u003e ).\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eAmong patients with node-negative disease, Recurrence Score group was significantly prognostic (P o 0.05) for subgroups analyzed by tumor grade ( \u003cref target=\"#fig_1\" type=\"figure\"\u003eFigure 2g\u003c/ref\u003e ) and tumor size ( \u003cref target=\"#fig_1\" type=\"figure\"\u003eFigure 2i\u003c/ref\u003e ), except for patients with very small tumors.\u003c/s\u003e\u003cs\u003eFor patients with tumors \u0026#x2A7D; 5 mm in size, the estimated risk is elevated in the group with Recurrence Score results \u0026#x2A7E; 31, although the estimate lacks precision (1.9%; 95% CI, 0.3-12.5%).\u003c/s\u003e\u003cs\u003eAmong patients with nodenegative disease and tumors 44 cm in size, Recurrence Score group was significantly prognostic (P = 0.005), but all three Recurrence Score groups have estimated 5-year BCSM of 2.4% or higher \u003cref target=\"#fig_1\" type=\"figure\"\u003e(Figure 2i\u003c/ref\u003e ).\u003c/s\u003e\u003cs\u003eFor patients with node-positive (N+(mic,1-3)) disease, those with higher Recurrence Score results generally had worse 5-year BCSM than those with lower results, regardless of tumor size ( \u003cref target=\"#fig_1\" type=\"figure\"\u003eFigure 2j\u003c/ref\u003e ).\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eWith respect to tumor grade, regardless of nodal status, 5-year BCSM generally increased with worsening grade, as expected \u003cref target=\"#fig_1\" type=\"figure\"\u003e(Figure 2g\u003c/ref\u003e ,h).\u003c/s\u003e\u003cs\u003eWithin grade categories, however, the group with Recurrence Score results o 18 consistently had low 5-year BCSM (o 1% for node-negative disease; o2% for node-positive (N+(mic,1-3)) disease), even for patients with high tumor grade.\u003c/s\u003e\u003cs\u003eFor patients with node-negative disease and Recurrence Score results \u0026#x2A7E; 31, 5-year BCSM was 42%, even for patients with low tumor grade.\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003chead\u003eMultivariable model with adjustment for baseline covariates\u003c/head\u003e\u003cp\u003e\u003cs\u003eThe effects of Recurrence Score results and potential confounding variables were assessed using a Cox regression model.\u003c/s\u003e\u003cs\u003eCompared with patients with a Recurrence Score result o18 and without adjusting for other covariates, patients with Recurrence Score results 18-30 and results \u0026#x2A7E; 31 had higher hazards for BCSM.\u003c/s\u003e\u003cs\u003eThese effects were modestly attenuated after adjustment for grade, tumor size, age, and race \u003cref target=\"#tab_1\" type=\"table\"\u003e(Table 2)\u003c/ref\u003e ; however, the Recurrence Score 18-30 and \u0026#x2A7E; 31 groups remain at significantly increased hazards (P o 0.001).\u003c/s\u003e\u003cs\u003eBecause Recurrence Score results are known to affect treatment decisions, an additional model was fit with a treatment interaction.\u003c/s\u003e\u003cs\u003eIn this model, Recurrence Score results remained prognostic among both patients for whom chemotherapy was reported as \u0026apos;yes\u0026apos; and as \u0026apos;no/unknown,\u0026apos; but the strength of the association was attenuated for those with chemotherapy reported as \u0026apos;yes\u0026apos; (P = 0.03 for covariate-adjusted interaction).\u003c/s\u003e\u003cs\u003eComparable models fitted using Recurrence Score result as a continuous linear variable were also significant for prognosis, with and without adjustment for covariates (P o0.001 for both).\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eIn the covariate-adjusted model, increases in the hazard of BCSM were significantly associated with poorly differentiated tumors (hazard ratio (HR) 2.1 (95% CI, 1.3-3.2),\u003c/s\u003e\u003cs\u003eP = 0.002), tumors 44 cm in size (HR 3.4 (95% CI, 1.3-8.7),\u003c/s\u003e\u003cs\u003eP = 0.010), age 70-79 years (HR 2.4 (95% CI, 1.2-5.0),\u003c/s\u003e\u003cs\u003eP = 0.014), and age \u0026#x2A7E; 80 years (HR 6.1 (95% CI, 2.6-14.3),\u003c/s\u003e\u003cs\u003eP o 0.001).\u003c/s\u003e\u003cs\u003ePatients with very small tumors (\u0026#x2A7D;5 mm) did not have significantly different outcomes than patients had with tumors 45 to 10 mm in size.\u003c/s\u003e\u003cs\u003eThe youngest patients (o 40 years) did not have significantly different outcomes than patients who were 40-49 years or 50-59 years of age.\u003c/s\u003e\u003cs\u003eIn contrast, older patients at the time of diagnosis (\u0026#x2A7E;70 years) had The multivariable model also demonstrated differences in outcomes by race.\u003c/s\u003e\u003cs\u003eAn alternate model, replacing race with Yost quintile, as a marker for neighborhood SES, also showed worsening outcomes with lower SES; however, neither race nor SES were significant when both terms were included in the same model, and both effects are relatively weak compared to the genomic and clinical factors.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eTAILORx clinical trial cutpoints Since its initial development, the 21-gene assay results report has used Recurrence Score cutpoints of 18 and 31, and has provided individualized risk estimates for the specific Recurrence Score result for each patient.\u003c/s\u003e\u003cs\u003eAlternative cutpoints, however, have been implemented in clinical trials.\u003c/s\u003e\u003cs\u003eThe ongoing TAILORx randomized trial uses cutpoints of 11 and 25 to define Recurrence Score categories o11, 11-25, and 425.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b11\" type=\"bibr\"\u003e13\u003c/ref\u003e Applying these alternative categories to our study cohort, the 5-year BCSM in the HR+, nodenegative, non-age-restricted cohort were 0.4% (95% CI, 0.2-0.6%)\u003c/s\u003e\u003cs\u003efor 7,281 patients with Recurrence Score results o 11, 0.7% (95% CI, 0.6-0.8%)\u003c/s\u003e\u003cs\u003efor 26,462 patients with Recurrence Score results 11-25, and 3.6% (95% CI, 3.0-4.4%)\u003c/s\u003e\u003cs\u003efor 6,391 patients with Recurrence Score results 425 (Po 0.001).\u003c/s\u003e\u003cs\u003eConsidering both the standard cutpoints and the TAILORx cutpoints, the 5-year BCSM for 10,589 patients with Recurrence Score results 18-24 and 3,905 patients with Recurrence Score results 25-30 were 1.0% (95% CI, 0.8-1.4%)\u003c/s\u003e\u003cs\u003eand 2.4% (95% CI, 1.8-3.2%),\u003c/s\u003e\u003cs\u003erespectively.\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003chead\u003eDISCUSSION\u003c/head\u003e\u003cp\u003e\u003cs\u003eOur prespecified primary analysis of the population-based SEER database electronically supplemented with Recurrence Score results showed that the Recurrence Score result was significantly associated with the likelihood of BCSM (P o0.001).\u003c/s\u003e\u003cs\u003eIn multivariable analysis that adjusted for the prognostic baseline covariates of patient age, tumor size, tumor grade, and race, as well as reported chemotherapy use, the Recurrence Score result remained strongly predictive of BCSM (P o0.001).\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eWe showed that patients with node-negative disease in the SEER program with Recurrence Score results o 18, who had low rates of chemotherapy use reported as \u0026apos;yes\u0026apos; (7%), had 5-year BCSM of 0.4% (95% CI, 0.3-0.6%), a finding that is consistent with those of earlier, prospective-retrospective clinical validation studies performed on archival specimens.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b7\" type=\"bibr\"\u003e9,\u003c/ref\u003e \u003cref target=\"#b9\" type=\"bibr\"\u003e11,\u003c/ref\u003e \u003cref target=\"#b15\" type=\"bibr\"\u003e17\u003c/ref\u003e For example, 5-year BCSM for patients with Recurrence Score results o18 was 0.9% (95% CI, 0.3-2.8%) in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 study and 1.1% (95% CI, 0.5-1.6%) in the Kaiser study (L.\u003c/s\u003e\u003cs\u003eHabel, personal communication).\u003c/s\u003e\u003cs\u003eThat our results for patients with Recurrence Score results o 18 were similar to earlier results, despite dissimilar time periods in which each cohort was enrolled, demonstrates the capacity of the Recurrence Score result to identify patients with excellent prognosis, regardless of the era in which they were diagnosed or the specific treatments they received.\u003c/s\u003e\u003cs\u003eMoreover, the favorable outcomes we observed in patients with node-negative disease and Recurrence Score results o18 confirm-and extend-findings of the TAILORx trial, the Clalit Health Services study, and the PlanB trial of the Women\u0026apos;s Healthcare Study Group in Germany, all of which reported excellent outcomes for patients with low Recurrence Score results.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b11\" type=\"bibr\"\u003e[13]\u003c/ref\u003e \u003cref target=\"#b12\" type=\"bibr\"\u003e[14]\u003c/ref\u003e \u003cref target=\"#b13\" type=\"bibr\"\u003e[15]\u003c/ref\u003e For patients with node-positive (N+(mic,1-3)) disease, the Recurrence Score result was strongly predictive of BCSM, despite the relatively short-median follow-up.\u003c/s\u003e\u003cs\u003eFor patients with Recurrence Score results o18, 23% of whom had chemotherapy use reported as \u0026apos;yes,\u0026apos; the 5-year BCSM was 1.0% (95% CI, 0.5-2.0%),\u003c/s\u003e\u003cs\u003esimilar to the 5-year BCSM observed for patients with nodenegative disease.\u003c/s\u003e\u003cs\u003eThese results in more than 4,600 patients with node-positive disease reconfirm the Recurrence Score results from the SWOG 8814 and ATAC studies showing that the 21-gene assay identifies a group of patients with node-positive disease and Recurrence Score results o 18 with favorable outcomes.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b9\" type=\"bibr\"\u003e11,\u003c/ref\u003e \u003cref target=\"#b10\" type=\"bibr\"\u003e12\u003c/ref\u003e The ongoing Treatment (Rx) for Positive Node, Endocrine Responsive Breast Cancer (RxPONDER) clinical trial, \u003cref target=\"#b16\" type=\"bibr\"\u003e18\u003c/ref\u003e in which patients with node-positive disease and Recurrence Score results o 25 are randomized to endocrine therapy with or without adjuvant chemotherapy, should provide more definitive information on the effect of chemotherapy.\u003c/s\u003e\u003cs\u003eOur SEER results provide prospective evidence that certain patients with node-positive disease and low Recurrence Score results have favorable 5-year BCSM, and reassurance that the randomization in RxPONDER was justified.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003ePrior to our study, there were relatively little data regarding Recurrence Score results and outcomes in younger and older patients with breast cancer.\u003c/s\u003e\u003cs\u003eFor example, only 3% of patients in the NSABP B-14 study, 19 5% in the ongoing TAILORx trial (J.\u003c/s\u003e\u003cs\u003eSparano, personal communication), and 0% in the ongoing MINDACT trial were older than 70 years.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b18\" type=\"bibr\"\u003e20\u003c/ref\u003e Our population-based SEER study is therefore noteworthy for providing the largest experience to date with patients \u0026#x2A7E; 70 years of age, including 4,647 with node-negative disease and 880 with node-positive \u003cref target=\"#fig_0\" type=\"figure\"\u003e(N+(mic,1-3)\u003c/ref\u003e ) disease, and with patients o40 years, including 1,480 with node-negative disease and 165 with node-positive (N+(mic,1-3)) disease.\u003c/s\u003e\u003cs\u003eOur study found that regardless of age, patients with Recurrence Score results o 18 had excellent outcomes: 5-year BCSM was o 1.3% in the node-negative group and o1.7% in the node-positive \u003cref target=\"#fig_0\" type=\"figure\"\u003e(N+(mic,1-3)\u003c/ref\u003e ) group.\u003c/s\u003e\u003cs\u003eImportantly, although younger age is considered an unfavorable prognostic factor, 21 the 5-year BCSM of 0.0% that we observed in 682 patients o40 years with node-negative disease and Recurrence Score results o18 indicates that the Recurrence Score assay identified a subset of very young patients that had excellent outcomes.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eWe noted that outcomes were especially poor for older patients with node-negative disease and Recurrence Score results \u0026#x2A7E; 31: 5-year BCSM was 10.4% for patients 70-79 years and 21.6% for patients \u0026#x2A7E; 80 years.\u003c/s\u003e\u003cs\u003eWithin this Recurrence Score group (\u0026#x2A7E;31), 72% of patients o70 years, but only 53% of patients \u0026#x2A7E; 70 years, had chemotherapy use reported as \u0026apos;yes.\u0026apos;\u003c/s\u003e\u003cs\u003ePrevious studies have reported that older women with breast cancer generally receive less aggressive treatment than younger patients do and are more likely to die from their disease.\u003c/s\u003e\u003cs\u003e22-25 Importantly, practice guidelines by the National Comprehensive Cancer Network on \u0026apos;Older Adult Oncology\u0026apos; acknowledge that older women with breast cancer \u0026apos;often do not receive \u0026apos;standard of care.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b23\" type=\"bibr\"\u003e26\u003c/ref\u003e \u0026apos; Clearly, as population demographics shift, it is imperative that we understand and take action to lessen BCSM in older patients.\u003c/s\u003e\u003cs\u003eA moredetailed analysis of the older population in SEER is underway to examine comorbidities, competing risks, and outcomes in patients with and without 21-gene assay testing.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eWe further show that the Recurrence Score result was significantly prognostic for BCSM in every subgroup of race, SES, and pathology (with the possible exception of tumors \u0026#x2A7D; 5 mm in size, although the general trend for this subgroup was consistent with observations made in subgroups with larger tumors).\u003c/s\u003e\u003cs\u003eFor several subgroups historically under-represented in clinical studies, including patients of lower SES and patients who identify as non-White, our results add substantially to the body of knowledge relating the Recurrence Score results to outcomes.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eFinally, Recurrence Score biology at diagnosis was a very strong predictor of BCSM but, as expected, was not predictive of othercause mortality.\u003c/s\u003e\u003cs\u003eAge was the strongest predictor of other-cause mortality.\u003c/s\u003e\u003cs\u003eIt will be important in future studies to assess in greater detail BCSM in the context of other-cause mortality and patient comorbidities.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eThe availability now of prospective outcomes for over 50,000 patients with Recurrence Score results across multiple studies carries implications for both clinical practice and breast cancer staging.\u003c/s\u003e\u003cs\u003eUse of clinical and pathologic factors alone (e.g., luminal A-like or luminal B-like) may be inadequate to select patients for consideration of adjuvant chemotherapy.\u003c/s\u003e\u003cs\u003eThe 21-gene Recurrence Score assay has the capacity to further risk-stratify within any clinical or pathologic category (including luminal A-like and luminal B-like), \u003cref target=\"#b24\" type=\"bibr\"\u003e27,\u003c/ref\u003e \u003cref target=\"#b25\" type=\"bibr\"\u003e28\u003c/ref\u003e based on tumor biology.\u003c/s\u003e\u003cs\u003eAt present, the American Joint Committee on Cancer (AJCC) is working to revise the current TNM breast cancer staging system, largely limited to anatomic information, to incorporate new molecular testing information.\u003c/s\u003e\u003cs\u003eCollaborations between SEER and diagnostic testing companies, such as the research model pioneered in this study, can provide evidence from large high-quality datasets to support updated criteria for cancer staging.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eIn general, observational studies can provide valuable information on diagnosis, treatment, and outcomes in actual clinical practice.\u003c/s\u003e\u003cs\u003eWhen very large, observational studies can provide new information about subgroups of patients that randomized clinical trials are often not powered to assess.\u003c/s\u003e\u003cs\u003eNonetheless, observational studies, like ours, have limitations.\u003c/s\u003e\u003cs\u003eFirst, data in the SEER Program are derived from patients who were not randomized to treatment.\u003c/s\u003e\u003cs\u003eThis potentially introduces bias and confounding factors for estimating treatment effects that cannot be fully controlled.\u003c/s\u003e\u003cs\u003eTo enhance the rigor of our large observational study, we applied the Good Research for Comparative Effectiveness (GRACE) Principles of good study design and implementation to the methodology and analyses.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b26\" type=\"bibr\"\u003e29\u003c/ref\u003e Second, the SEER Program collects no information on breast cancer recurrence and progression.\u003c/s\u003e\u003cs\u003eThird, chemotherapy use is under-reported in SEER.\u003c/s\u003e\u003cs\u003eAlthough the magnitude of underreporting is unknown, one study involving the Medicare population suggested a 30% relative under-ascertainment. \u003cref target=\"#b27\" type=\"bibr\"\u003e30\u003c/ref\u003e For the reasons of under-reporting of chemotherapy use and selection bias in who elected to get chemotherapy, we do not report BCSM by treatment choice.\u003c/s\u003e\u003cs\u003eAlthough we do report the percent for whom chemotherapy is reported as \u0026apos;yes\u0026apos; versus \u0026apos;no/unknown\u0026apos; in various subgroups, the limitations of this variable should be kept in mind when interpreting these results.\u003c/s\u003e\u003cs\u003eAt the time of this analysis with SEER survival follow-up only through 2012, the extent of patient follow-up beyond 5 years was limited.\u003c/s\u003e\u003cs\u003eHowever, with the large sample size, the confidence intervals for the 5-year BCSM estimates are narrow.\u003c/s\u003e\u003cs\u003eMoreover, the reported overall benefit of chemotherapy has been observed by 5 years.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b28\" type=\"bibr\"\u003e31\u003c/ref\u003e Finally, other multigene signatures for breast recurrence risk were not included in this analysis.\u003c/s\u003e\u003cs\u003eIt should be noted that the 21-gene assay accounted for 493% of tests reported to SEER by manual collection in 2010-2012.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eOur study nevertheless had a number of strengths.\u003c/s\u003e\u003cs\u003eFirst, ours is the largest-to-date study of prospective outcomes based on Recurrence Score results in node-negative and node-positive disease.\u003c/s\u003e\u003cs\u003eSecond, the SEER Program is remarkable for its stringent ascertainment of population-based patient-specific data at the time of diagnosis and at the time of death.\u003c/s\u003e\u003cs\u003eThird, the populationbased nature of the SEER registries combined with the size of the database of the Genomic Health Clinical Laboratory (the only laboratory that performs the 21-gene assay) ensures that study results reflect real-world practices.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eIn the future, we plan to conduct additional analyses, including among others: (a) continued follow-up of the SEER registries to encompass an ever-increasing number of patients; (b) in-depth analyses of important subgroups by, for example, race, ethnicity, SES, and sex; (c) determination of propensity scores for chemotherapy benefit; (d) assessment of factors that influence assay ordering, including geography; and (e) comparison of manually collected and Genomic Health Clinical Laboratory-reported Recurrence Score results.\u003c/s\u003e\u003cs\u003eIn addition, we plan to conduct an analogous analysis after merging with the SEER-Medicare database.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eIn conclusion, this study represents a new model for collaboration between National Cancer Institute, SEER registries, and industry to more efficiently and completely capture important genomic test results to inform understanding of \u0026apos;real-world\u0026apos; oncology practice.\u003c/s\u003e\u003cs\u003eOur study results strongly reinforce the findings of the prospectively designed TAILORx trial, other prospective outcomes studies, and numerous earlier prospective-retrospective validation studies.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b7\" type=\"bibr\"\u003e[9]\u003c/ref\u003e \u003cref target=\"#b8\" type=\"bibr\"\u003e[10]\u003c/ref\u003e \u003cref target=\"#b9\" type=\"bibr\"\u003e[11]\u003c/ref\u003e \u003cref target=\"#b10\" type=\"bibr\"\u003e[12]\u003c/ref\u003e \u003cref target=\"#b11\" type=\"bibr\"\u003e[13]\u003c/ref\u003e \u003cref target=\"#b12\" type=\"bibr\"\u003e[14]\u003c/ref\u003e \u003cref target=\"#b13\" type=\"bibr\"\u003e[15]\u003c/ref\u003e \u003cref target=\"#b15\" type=\"bibr\"\u003e17\u003c/ref\u003e Our SEER study provides additional evidence in 444,000 patients with node-negative and node-positive (N+(mic,1-3)) disease that the 21-gene assay accurately predicts prospective outcomes, independent of patient age, tumor size, and tumor grade.\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003chead\u003eMATERIALS AND METHODS\u003c/head\u003e\u003c/div\u003e\u003cdiv subtype=\"dataseer\"\u003e\u003chead\u003eStudy population\u003c/head\u003e\u003cp\u003e\u003cs\u003eThe electronic linkage of the 21-gene Oncotype DX Breast Recurrence Score assay (Genomic Health, Inc., Redwood City, CA, USA) results from the Genomic Health Clinical Laboratory database with the SEER registries database was based on protected health information included in the these databases.\u003c/s\u003e\u003cs\u003eThe linkage was performed by Information Management Services (IMS, Calverton, MD, USA), a National Cancer Institute contractor that manages cancer surveillance data for SEER Program registries, using the Link Plus software (Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, National Program of Cancer Registries; Atlanta, GA, USA), a deterministic SAS algorithm, and manual adjudication of partial matches by registries staff.\u003c/s\u003e\u003cs\u003eDe-identified data were released to the study team after SEER approval of a custom data request.\u003c/s\u003e\u003cs\u003eThis linkage allowed for the inclusion of Recurrence Score results from 2004 and for more complete Recurrence Score capture from 2010 forward (manuscript in preparation).\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eThe primary survival analysis cohort, statistical methodology, and study end point were prespecified before the data linkage was performed.\u003c/s\u003e\u003cs\u003eThe primary survival analysis cohort was specified as all patients in the SEER research database diagnosed between 1 January 2004 and 31 December 2011 who had lymph node-negative, HR+, HER2-negative, primary invasive breast cancer, and a Recurrence Score result in the Genomic Health Clinical Laboratory database.\u003c/s\u003e\u003cs\u003eStandard cutoffs that define risk groups by Recurrence Score results are as follows: low (o18), intermediate \u003cref target=\"#b16\" type=\"bibr\"\u003e(18)\u003c/ref\u003e \u003cref target=\"#b17\" type=\"bibr\"\u003e(19)\u003c/ref\u003e \u003cref target=\"#b18\" type=\"bibr\"\u003e(20)\u003c/ref\u003e \u003cref target=\"#b19\" type=\"bibr\"\u003e(21)\u003c/ref\u003e \u003cref type=\"bibr\"\u003e(22)\u003c/ref\u003e \u003cref target=\"#b20\" type=\"bibr\"\u003e(23)\u003c/ref\u003e \u003cref target=\"#b21\" type=\"bibr\"\u003e(24)\u003c/ref\u003e \u003cref target=\"#b22\" type=\"bibr\"\u003e(25)\u003c/ref\u003e \u003cref target=\"#b23\" type=\"bibr\"\u003e(26)\u003c/ref\u003e \u003cref target=\"#b24\" type=\"bibr\"\u003e(27)\u003c/ref\u003e \u003cref target=\"#b25\" type=\"bibr\"\u003e(28)\u003c/ref\u003e \u003cref target=\"#b26\" type=\"bibr\"\u003e(29)\u003c/ref\u003e \u003cref target=\"#b27\" type=\"bibr\"\u003e(30)\u003c/ref\u003e , and high (\u0026#x2A7E;31).\u003c/s\u003e\u003cs\u003ePatients were excluded if they had metastatic disease, any previous history of invasive cancer (but not prior ductal carcinoma in situ), or multiple Recurrence Score results for any reason (e.g., multifocal disease or concurrent primary tumors).\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eTo be more consistent with the patient populations of the NSABP B-14 and Kaiser clinical validation studies, \u003cref target=\"#b7\" type=\"bibr\"\u003e9,\u003c/ref\u003e \u003cref target=\"#b15\" type=\"bibr\"\u003e17\u003c/ref\u003e the primary survival analysis was restricted to patients with lymph node-negative, HR+ HER2-negative breast cancer who were 40-84 years of age at diagnosis.\u003c/s\u003e\u003cs cert=\"0.9801158905029297\" id=\"dataset-2\" type=\"tabular data\"\u003eSecondary survival analyses of various subgroups included patients of all ages and patients with node-positive disease.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs cert=\"0.33528584241867065\" id=\"dataset-3\" type=\"genetic data\"\u003ePatients were considered HR+ if their tumors were estrogen receptor-or progesterone receptor-positive (ER+ or PR+) by the SEER-reported ER and PR immunohistochemistry results (borderline results were considered positive) and by the 21-gene assay quantitative reverse transcription-PCR (RT-PCR) single-gene ER or PR results.\u003c/s\u003e\u003cs cert=\"0.7117895483970642\" id=\"dataset-4\" type=\"tabular data\"\u003ePatients were considered node-negative or node-positive based on the data collected by SEER.\u003c/s\u003e\u003cs\u003eAccording to the AJCC 6th and 7th edition, 32 micrometastases were considered lymph nodepositive and isolated tumor cells were considered lymph node-negative.\u003c/s\u003e\u003cs\u003eThe SEER database includes no information on HER2 status prior to 2010.\u003c/s\u003e\u003cs\u003eThus, HER2-negative patients were identified among those with Recurrence Score results who had 21-gene assay quantitative RT-PCR single-gene HER2 scores \u0026#x2A7D; 11.5.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b30\" type=\"bibr\"\u003e[33]\u003c/ref\u003e \u003cref target=\"#b31\" type=\"bibr\"\u003e[34]\u003c/ref\u003e \u003cref target=\"#b32\" type=\"bibr\"\u003e[35]\u003c/ref\u003e Rare cases in which tumors were classified in SEER as undifferentiated or anaplastic were considered to be poorly differentiated.\u003c/s\u003e\u003cs cert=\"0.9677854180335999\" id=\"dataset-5\" type=\"tabular data\"\u003eBoth male and female patients were included in all analyses.\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv subtype=\"dataseer\"\u003e\u003chead\u003eEnd point\u003c/head\u003e\u003cp\u003e\u003cs\u003eThe study end point for all outcome analyses was BCSM.\u003c/s\u003e\u003cs cert=\"0.9685858488082886\" id=\"dataset-6\" type=\"tabular data\"\u003eUnderlying causes of death (CODs) were ascertained by the SEER registries through linkages with state death certificates and the National Death Index from the National Center for Health Statistics.\u003c/s\u003e\u003cs\u003e\u003cref type=\"bibr\"\u003e36\u003c/ref\u003e In addition, vital status was ascertained through linkages with other sources, such as state Departments of Motor Vehicles, state voter registration databases, and the Social Security Administration.\u003c/s\u003e\u003cs\u003eTo correct the known errors with COD attribution, the SEER program developed a special COD variable that maps underlying CODs to the primary cancer diagnosis.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b33\" type=\"bibr\"\u003e37\u003c/ref\u003e We used this variable to assign a broad set of CODs to capture deaths from breast cancer among patients diagnosed with an incident breast cancer in SEER.\u003c/s\u003e\u003cs\u003ePatients who did not die of breast cancer were censored at time of last follow-up \u003cref type=\"bibr\"\u003e(31 December 2011)\u003c/ref\u003e or at time of death from other causes.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eTo protect patient confidentiality, time to event in SEER is captured in months rather than days.\u003c/s\u003e\u003cs\u003eTherefore, actuarial methods rather than Kaplan-Meier methods were utilized for event and freedom-from-event calculations.\u003c/s\u003e\u003cs\u003eFive-year BCSM was selected as the summary outcome measure of greatest importance based on its importance as a clinically meaningful end point and limited BCSM follow-up beyond 5 years.\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv subtype=\"dataseer\"\u003e\u003chead\u003eStatistical analysis\u003c/head\u003e\u003cp\u003e\u003cs\u003eThe primary survival analysis was prespecified to be performed on eligible patients in the three categorical Recurrence Score groups based on the standard 21-gene assay Recurrence Score cutpoints: o18, 18-30, or \u0026#x2A7E; 31.\u003c/s\u003e\u003cs cert=\"0.9669367074966431\" id=\"dataset-7\" type=\"tabular data\"\u003eThe continuous Recurrence Score result (0-100) was evaluated in secondary analyses.\u003c/s\u003e\u003cs\u003eActuarial estimates of survival were computed through 5 years with 95% CIs.\u003c/s\u003e\u003cs\u003eThe log-rank test was used to compare the three Recurrence Score groups.\u003c/s\u003e\u003cs\u003eHazard ratios were calculated using Cox regression models, which were fit using SAS PROC PHREG (SAS/STAT version 9.4, SAS Institute Inc., Cary, NC, USA).\u003c/s\u003e\u003cs cert=\"0.9654628038406372\" id=\"dataset-8\" type=\"tabular data\"\u003eProportional hazards assumptions were assessed and met in the final models.\u003c/s\u003e\u003cs\u003eTwo sets of prognostic models were fit: one set used the three-category Recurrence Score group variable and the second, as a sensitivity analysis, used the continuous Recurrence Score result.\u003c/s\u003e\u003c/p\u003e\u003cp\u003e\u003cs\u003eIt is important to note that the Recurrence Score result is provided to patients and physicians to guide treatment decisions.\u003c/s\u003e\u003cs\u003eAlthough the result is one of many factors that influence treatment decision-making, the group with Recurrence Score results o 18 has been shown in multiple previous studies to have a much lower rate of reported chemotherapy use than the groups with higher Recurrence Score results.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b34\" type=\"bibr\"\u003e[38]\u003c/ref\u003e \u003cref target=\"#b35\" type=\"bibr\"\u003e[39]\u003c/ref\u003e \u003cref target=\"#b36\" type=\"bibr\"\u003e[40]\u003c/ref\u003e \u003cref target=\"#b37\" type=\"bibr\"\u003e[41]\u003c/ref\u003e Thus, the difference in BCSM curves among the three Recurrence Score groups was expected to be smaller, in percentage terms, than if all patients were treated with hormonal therapy alone.\u003c/s\u003e\u003cs\u003eAdjusting for treatment was not straightforward because treatment itself is influenced by the Recurrence Score result and there is a known issue with ascertainment bias for treatment.\u003c/s\u003e\u003cs\u003eAs a sensitivity analysis, multivariable models were fit including Recurrence Score results, treatment, and an interaction in the model; however, these models should not be used to evaluate comparative effectiveness.\u003c/s\u003e\u003cs cert=\"0.8369592428207397\" id=\"dataset-9\" type=\"tabular data\"\u003eSubgroup analyses were conducted by age, race, tumor size, tumor grade, and SES Index.\u003c/s\u003e\u003cs\u003eThe SES Index was created by SEER and is based on each patient\u0026apos;s census-tract at-diagnosis attributes reflected by the Yost composite Index.\u003c/s\u003e\u003cs\u003eTo further protect patients\u0026apos; privacy, the SES Index is categorized in quintiles.\u003c/s\u003e\u003cs\u003e\u003cref target=\"#b38\" type=\"bibr\"\u003e42\u003c/ref\u003e\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003cfigure xml:id=\"fig_0\"\u003e\u003chead\u003eFigure 1 .\u003c/head\u003e\u003clabel\u003e1\u003c/label\u003e\u003cfigDesc\u003e\u003cdiv\u003e\u003cp\u003e\u003cs\u003eFive-year estimates of breast-cancer-specific mortality, by Recurrence Score group (prespecified primary analysis).\u003c/s\u003e\u003cs\u003ePatients with HR+, HER2-negative, node-negative breast cancer who had Recurrence Score (RS) results o18 (green), 18-30 (yellow), or \u0026#x2A7E; 31 (red) were included in the primary analysis.\u003c/s\u003e\u003cs\u003eFive-year estimates of breast-cancer-specific mortality (BCSM) with 95% CIs (green, yellow, and red shading) were 0.4% (0.3-0.6%) in the RS o18 group, 1.4% (1.1-1.7%) in the RS 18-30 group, and 4.4% (3.4-5.6%) in the RS \u0026#x2A7E; 31 group.\u003c/s\u003e\u003cs\u003eFive-year estimates of BCSM \u0026#xB1; s.e. are shown to the right of their respective lines.\u003c/s\u003e\u003cs\u003eNumbers of patients at risk in each group are shown beneath the graph.\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003c/figDesc\u003e\u003c/figure\u003e\u003cfigure xml:id=\"fig_1\"\u003e\u003chead\u003eFigure 2 .\u003c/head\u003e\u003clabel\u003e2\u003c/label\u003e\u003cfigDesc\u003e\u003cdiv\u003e\u003cp\u003e\u003cs\u003eFive-year estimates of breast cancer-specific mortality, by Recurrence Score group (subgroup analyses).\u003c/s\u003e\u003cs\u003ePatients with HR+, HER2-negative, node-negative (a,c,e,g,i) and node-positive (micrometastases up to three positive nodes; b,d,f,h,j) breast cancer who had Recurrence Score (RS) results o18 (green), 18-30 (yellow), or \u0026#x2A7E; 31 (red) were included in subgroup analyses by age (a,b), race (c,d), socioeconomic status (e,f) as defined by the Yost composite index, \u003cref target=\"#b37\" type=\"bibr\"\u003e41\u003c/ref\u003e tumor grade (g,h), and tumor size (i,j).\u003c/s\u003e\u003cs\u003eFive-year estimates of breastcancer-specific mortality (BCSM) \u0026#xB1; s.e. are shown.\u003c/s\u003e\u003cs\u003ePercentages of patients with chemotherapy use reported as \u0026apos;yes\u0026apos; as a proportion of all patients (\u0026apos;yes\u0026apos; or \u0026apos;no/unknown\u0026apos; chemotherapy use) are shown beneath the graph.\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003c/figDesc\u003e\u003c/figure\u003e\u003cfigure xml:id=\"fig_2\"\u003e\u003chead\u003eFigure 2 .\u003c/head\u003e\u003clabel\u003e2\u003c/label\u003e\u003cfigDesc\u003e\u003cdiv\u003e\u003cp\u003e\u003cs\u003eContinued.significantly\u003c/s\u003e\u003cs\u003eworse BCSM in both the unadjusted and adjusted models.\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003c/figDesc\u003e\u003c/figure\u003e\u003cfigure type=\"table\" xml:id=\"tab_0\"\u003e\u003chead\u003eTable 1 .\u003c/head\u003e\u003clabel\u003e1\u003c/label\u003e\u003cfigDesc\u003e\u003cdiv\u003e\u003cp\u003e\u003cs\u003ePatient demographics, by nodal status and Recurrence Score assay status (N = 241,681)\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003c/figDesc\u003e\u003ctable\u003e\u003crow\u003e\u003ccell\u003eCategory\u003c/cell\u003e\u003ccell\u003eParameter\u003c/cell\u003e\u003ccell cols=\"2\"\u003eNode-negative, HR+ (N = 184,190)\u003c/cell\u003e\u003ccell cols=\"2\"\u003eNode-positive (N+(mic,1-3)) a , HR+ (N = 57,491)\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell/\u003e\u003ccell\u003eHER2 \u0026#x2212; With RS\u003c/cell\u003e\u003ccell\u003eHER2 \u0026#xB1; b Without RS\u003c/cell\u003e\u003ccell\u003eHER2 \u0026#x2212; With RS\u003c/cell\u003e\u003ccell\u003eHER2 \u0026#xB1; b Without RS\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell/\u003e\u003ccell\u003e(N = 40,134)\u003c/cell\u003e\u003ccell\u003e(N = 144,056)\u003c/cell\u003e\u003ccell\u003e(N = 4,691)\u003c/cell\u003e\u003ccell\u003e(N = 52,800)\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell/\u003e\u003ccell\u003en (%)\u003c/cell\u003e\u003ccell\u003en (%)\u003c/cell\u003e\u003ccell\u003en (%)\u003c/cell\u003e\u003ccell\u003en (%)\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell\u003eAge\u003c/cell\u003e\u003ccell\u003eo40 years\u003c/cell\u003e\u003ccell\u003e1,480 (3.7)\u003c/cell\u003e\u003ccell\u003e4,827 (3.4)\u003c/cell\u003e\u003ccell\u003e165 (3.5)\u003c/cell\u003e\u003ccell\u003e3,889 (7.4)\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003e40-49 years\u003c/cell\u003e\u003ccell\u003e9,350 (23.3)\u003c/cell\u003e\u003ccell\u003e21,492 (14.9)\u003c/cell\u003e\u003ccell\u003e853 (18.2)\u003c/cell\u003e\u003ccell\u003e12,513 (23.7)\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003e50-59 years\u003c/cell\u003e\u003ccell\u003e12,744 (31.8)\u003c/cell\u003e\u003ccell\u003e31,230 (21.7)\u003c/cell\u003e\u003ccell\u003e1,375 (29.3)\u003c/cell\u003e\u003ccell\u003e14,032 (26.6)\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003e60-69 years\u003c/cell\u003e\u003ccell\u003e11,913 (29.7)\u003c/cell\u003e\u003ccell\u003e35,676 (24.8)\u003c/cell\u003e\u003ccell\u003e1,418 (30.2)\u003c/cell\u003e\u003ccell\u003e11,536 (21.8)\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003e70-79 years\u003c/cell\u003e\u003ccell\u003e4,173 (10.4)\u003c/cell\u003e\u003ccell\u003e30,548 (21.2)\u003c/cell\u003e\u003ccell\u003e778 (16.6)\u003c/cell\u003e\u003ccell\u003e6,952 (13.2)\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003e\u0026#x2A7E; 80 years\u003c/cell\u003e\u003ccell\u003e474 (1.2)\u003c/cell\u003e\u003ccell\u003e20,283 (14.1)\u003c/cell\u003e\u003ccell\u003e102 (2.2)\u003c/cell\u003e\u003ccell\u003e3,878 (7.3)\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell\u003eSex\u003c/cell\u003e\u003ccell\u003eMale\u003c/cell\u003e\u003ccell\u003e235 (0.6)\u003c/cell\u003e\u003ccell\u003e999 (0.7)\u003c/cell\u003e\u003ccell\u003e34 (0.7)\u003c/cell\u003e\u003ccell\u003e559 (1.1)\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003eFemale\u003c/cell\u003e\u003ccell\u003e39,899 (99.4)\u003c/cell\u003e\u003ccell\u003e143,057 (99.3)\u003c/cell\u003e\u003ccell\u003e4,657 (99.3)\u003c/cell\u003e\u003ccell\u003e52,241 (98.9)\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell/\u003e\u003ccell/\u003e\u003ccell/\u003e\u003ccell/\u003e\u003ccell\u003eresult (by\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell cols=\"6\"\u003ereverse transcription-PCR); includes patients with HER2-positive breast cancer in cohorts without Recurrence Score results because HER2 status was not\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell cols=\"2\"\u003ereported to SEER before 2010.\u003c/cell\u003e\u003ccell/\u003e\u003ccell/\u003e\u003ccell/\u003e\u003ccell/\u003e\u003c/row\u003e\u003crow\u003e\u003ccell cols=\"3\"\u003ec Among patients in the cohort with nonmissing information.\u003c/cell\u003e\u003ccell/\u003e\u003ccell/\u003e\u003ccell/\u003e\u003c/row\u003e\u003c/table\u003e\u003cnote\u003eAbbreviations: CT, chemotherapy; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; RS, Recurrence Score result.a Excludes patients with \u0026#x2A7E; 4 positive nodes or unknown/missing nodal status.b Excludes patients with HER2-positive breast cancer in cohorts with Recurrence Score results, based on 21-gene assay quantitative single-gene HER2d Includes undifferentiated and anaplastic tumors.\u003c/note\u003e\u003c/figure\u003e\u003cfigure type=\"table\" xml:id=\"tab_1\"\u003e\u003chead\u003eTable 2 .\u003c/head\u003e\u003clabel\u003e2\u003c/label\u003e\u003cfigDesc\u003e\u003cdiv\u003e\u003cp\u003e\u003cs\u003eMultivariable model for breast-cancer-specific mortality (patients with hormone-receptor-positive, HER2-negative, node-negative breast cancer, N = 40,134)CharacteristicEffect Unadjusted HR (95% CI) Unadjusted P value a Adjusted HR (95% CI) Adjusted P value a\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003c/figDesc\u003e\u003ctable\u003e\u003crow\u003e\u003ccell\u003eRS group (versus RS o18)\u003c/cell\u003e\u003ccell\u003eRS 18-30\u003c/cell\u003e\u003ccell\u003e3.1 (2.3, 4.3)\u003c/cell\u003e\u003ccell\u003eo 0.001\u003c/cell\u003e\u003ccell\u003e3.0 (2.1, 4.2)\u003c/cell\u003e\u003ccell\u003eo 0.001\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003eRS \u0026#x2A7E; 31\u003c/cell\u003e\u003ccell\u003e11.0 (7.8, 15.5)\u003c/cell\u003e\u003ccell/\u003e\u003ccell\u003e7.8 (5.3, 11.6)\u003c/cell\u003e\u003ccell/\u003e\u003c/row\u003e\u003crow\u003e\u003ccell\u003eTumor grade (versus well-\u003c/cell\u003e\u003ccell\u003eModerately\u003c/cell\u003e\u003ccell\u003e2.2 (1.5, 3.4)\u003c/cell\u003e\u003ccell\u003eo 0.001\u003c/cell\u003e\u003ccell\u003e1.6 (1.0, 2.4)\u003c/cell\u003e\u003ccell\u003e0.005\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell\u003edifferentiated)\u003c/cell\u003e\u003ccell\u003edifferentiated\u003c/cell\u003e\u003ccell/\u003e\u003ccell/\u003e\u003ccell/\u003e\u003ccell/\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003ePoorly differentiated b\u003c/cell\u003e\u003ccell\u003e5.5 (3.7, 8.4)\u003c/cell\u003e\u003ccell/\u003e\u003ccell\u003e2.1 (1.3, 3.2)\u003c/cell\u003e\u003ccell/\u003e\u003c/row\u003e\u003crow\u003e\u003ccell\u003eTumor size (versus \u0026#x2A7D;5 mm)\u003c/cell\u003e\u003ccell\u003e45 to 10 mm\u003c/cell\u003e\u003ccell\u003e0.6 (0.3, 1.4)\u003c/cell\u003e\u003ccell\u003eo 0.001\u003c/cell\u003e\u003ccell\u003e0.7 (0.3, 1.6)\u003c/cell\u003e\u003ccell\u003eo 0.001\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003e410 to 20 mm\u003c/cell\u003e\u003ccell\u003e0.9 (0.4, 2.0)\u003c/cell\u003e\u003ccell/\u003e\u003ccell\u003e0.9 (0.4, 2.1)\u003c/cell\u003e\u003ccell/\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003e420 to 40 mm\u003c/cell\u003e\u003ccell\u003e2.5 (1.2, 5.4)\u003c/cell\u003e\u003ccell/\u003e\u003ccell\u003e1.9 (0.8, 4.3)\u003c/cell\u003e\u003ccell/\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003e440 mm\u003c/cell\u003e\u003ccell\u003e4.5 (1.9, 10.7)\u003c/cell\u003e\u003ccell/\u003e\u003ccell\u003e3.4 (1.3, 8.7)\u003c/cell\u003e\u003ccell/\u003e\u003c/row\u003e\u003crow\u003e\u003ccell\u003eAge (versus o40 years)\u003c/cell\u003e\u003ccell\u003e40-49\u003c/cell\u003e\u003ccell\u003e0.7 (0.3, 1.4)\u003c/cell\u003e\u003ccell\u003eo 0.001\u003c/cell\u003e\u003ccell\u003e0.8 (0.4, 1.7)\u003c/cell\u003e\u003ccell\u003eo 0.001\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003e50-59\u003c/cell\u003e\u003ccell\u003e0.8 (0.4, 1.6)\u003c/cell\u003e\u003ccell/\u003e\u003ccell\u003e0.9 (0.5, 1.9)\u003c/cell\u003e\u003ccell/\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003e60-69\u003c/cell\u003e\u003ccell\u003e1.3 (0.7, 2.7)\u003c/cell\u003e\u003ccell/\u003e\u003ccell\u003e1.4 (0.7, 2.8)\u003c/cell\u003e\u003ccell/\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003e70-79\u003c/cell\u003e\u003ccell\u003e2.6 (1.3, 5.3)\u003c/cell\u003e\u003ccell/\u003e\u003ccell\u003e2.4 (1.2, 5.0)\u003c/cell\u003e\u003ccell/\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003e80-89\u003c/cell\u003e\u003ccell\u003e7.3 (3.2, 16.7)\u003c/cell\u003e\u003ccell/\u003e\u003ccell\u003e6.1 (2.6, 14.3)\u003c/cell\u003e\u003ccell/\u003e\u003c/row\u003e\u003crow\u003e\u003ccell\u003eRace (versus White)\u003c/cell\u003e\u003ccell\u003eBlack\u003c/cell\u003e\u003ccell\u003e1.9 (1.3, 2.7)\u003c/cell\u003e\u003ccell\u003e0.008\u003c/cell\u003e\u003ccell\u003e1.7 (1.1, 2.5)\u003c/cell\u003e\u003ccell\u003e0.036\u003c/cell\u003e\u003c/row\u003e\u003crow\u003e\u003ccell/\u003e\u003ccell\u003eOther\u003c/cell\u003e\u003ccell\u003e0.9 (0.5, 1.4)\u003c/cell\u003e\u003ccell/\u003e\u003ccell\u003e0.9 (0.5, 1.5)\u003c/cell\u003e\u003ccell/\u003e\u003c/row\u003e\u003c/table\u003e\u003cnote\u003eAbbreviations: CI, confidence interval; CT, chemotherapy; HR, hazard ratio; RS, Recurrence Score result.a Likelihood ratio P value.b Includes undifferentiated and anaplastic tumors.\u003c/note\u003e\u003c/figure\u003e\u003cnote place=\"foot\"\u003e\u0026#xA9; 2016 Breast Cancer Research Foundation/Macmillan Publishers Limited\u003c/note\u003e\u003cnote place=\"foot\"\u003enpj Breast Cancer (2016) 16017 \u0026#xA9; 2016 Breast Cancer Research Foundation/Macmillan Publishers Limited\u003c/note\u003e\u003cnote place=\"foot\"\u003e\u0026#xA9; 2016 Breast Cancer Research Foundation/Macmillan Publishers Limited npj Breast Cancer (2016) 16017\u003c/note\u003e\u003cnote n=\"4\" place=\"foot\"\u003enpj Breast Cancer (2016) 16017 \u0026#xA9; 2016 Breast Cancer Research Foundation/Macmillan Publishers Limited\u003c/note\u003e\u003c/body\u003e\u003cback\u003e\u003cdiv type=\"acknowledgement\"\u003e\u003cdiv\u003e\u003chead\u003eACKNOWLEDGMENTS\u003c/head\u003e\u003cp\u003e\u003cs\u003eWe acknowledge Anna Lau for medical writing and editorial assistance, and Cindy Loman for statistical graphics support.\u003c/s\u003e\u003cs\u003eThe ideas and opinions expressed herein are those of the author(s) and endorsement by any State, Department of Public Health, the National Cancer Institute, the Centers for Disease Control and Prevention, or their Contractors and Subcontractors is not intended nor should be inferred.\u003c/s\u003e\u003cs\u003eThe Surveillance, Epidemiology and End Results (SEER) Program is funded by the National Cancer Institute (NCI).\u003c/s\u003e\u003cs\u003eGenomic Health performed the work to electronically submit the Recurrence Score results, but provided no funding for this study.\u003c/s\u003e\u003cs\u003eSEER\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv type=\"annex\"\u003e\u003cdiv\u003e\u003cp\u003e\u003cs\u003eregistries were supported as follows: California-the collection of cancer incidence data used in this study was supported by: the California Department of Public Health pursuant to California Health and Safety Code Section 103885; the Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries (NPCR), under cooperative agreement 5NU58DP003862-04/DP003862; the NCI SEER Program, under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute.\u003c/s\u003e\u003cs\u003eGeorgia-this work was supported by the NCI, under contract HHSN261201300015I, task order HHSN26100006, and by the CDC, under cooperative agreement 5/U58/ DP003875-03.\u003c/s\u003e\u003cs\u003eHawaii-this work was supported by the NCI, under contract HHSN261201300009I, task order HHSN26100005, and by the University of Hawaii Cancer Center.\u003c/s\u003e\u003cs\u003eIowa-this work was supported by the NCI, under contract HHSN261201300020I, task order HHSN26100006, and by the University of Iowa Holden Comprehensive Cancer Center Support Grant through NCI grant 2P30CA086862-11.\u003c/s\u003e\u003cs\u003eKentucky-collection of the data by the Kentucky Cancer Registry used in this research project was supported by the NCI SEER, under contract HHSN2612013000131, and by the CDC NPCR, under cooperative agreement 5NU58DP003907-04-00.\u003c/s\u003e\u003cs\u003eLouisiana-this work was supported by the NCI SEER Program, under contract HHSN261201300016I, task order HHSN26100006, and by the Louisiana State University Health Sciences Center School of Public Health.\u003c/s\u003e\u003cs\u003eMichigan-this work was supported by the NCI, under contract HHSN261201300011I; the Karmanos Cancer Institute and Wayne State University Comprehensive Cancer Center Support Grant through NCI grant P30CA022453; and institutional funds from the Karmanos Cancer Institute and Wayne State University.\u003c/s\u003e\u003cs\u003eNew Mexico-this work was supported by the NCI, under contract HHSN26120130010I, task order HHSN26100005, and by the University of New Mexico Comprehensive Cancer Center Support Grant through NCI grant 2P30CA118100-1.\u003c/s\u003e\u003cs\u003eUtah-this work was supported by the University of Utah and Huntsman Cancer Institute Foundation.\u003c/s\u003e\u003cs\u003eWashingtonthis work was supported by the NCI, under contract HHSN26120130012I, task order HHSN26100005, and by the Fred Hutchinson Cancer Research Center Support Grant through NCI grant 5P30CA015704-41.\u003c/s\u003e\u003cs\u003eR.C. has received research funding from Genomic Health.\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003chead\u003eCOMPETING INTERESTS\u003c/head\u003e\u003cp\u003e\u003cs\u003eD.P.M., N.G., F.L.B., and S.S. are employees of Genomic Health.\u003c/s\u003e\u003cs\u003eThe remaining authors declare no conflict of interest.\u003c/s\u003e\u003c/p\u003e\u003c/div\u003e\u0009\u0009\u0009\u003c/div\u003e\u003cdiv type=\"references\"\u003e\u003clistBibl\u003e\u003cbiblStruct xml:id=\"b0\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eAge-related disparity in immediate prognosis of patients with triple-negative breast cancer: A population-based study from SEER cancer registries\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eW\u003c/forename\u003e\u003csurname\u003eZhu\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eE\u003c/forename\u003e\u003cforename type=\"middle\"\u003eA\u003c/forename\u003e\u003csurname\u003ePerez\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eR\u003c/forename\u003e\u003csurname\u003eHong\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eQ\u003c/forename\u003e\u003csurname\u003eLi\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eB\u003c/forename\u003e\u003csurname\u003eXu\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003ePLoS ONE\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e10\u003c/biblScope\u003e\u003cbiblScope unit=\"page\"\u003e128345\u003c/biblScope\u003e\u003cdate type=\"published\" when=\"2015\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b1\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eMeta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eL\u003c/forename\u003e\u003cforename type=\"middle\"\u003eA\u003c/forename\u003e\u003csurname\u003eNewman\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eJ. Clin. Oncol\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e24\u003c/biblScope\u003e\u003cbiblScope from=\"1342\" to=\"1349\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2006\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b2\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eDisparities in breast cancer characteristics and outcomes by race/ethnicity\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eS\u003c/forename\u003e\u003cforename type=\"middle\"\u003eL\u003c/forename\u003e\u003csurname\u003eOoi\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eM\u003c/forename\u003e\u003cforename type=\"middle\"\u003eE\u003c/forename\u003e\u003csurname\u003eMartinez\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eC\u003c/forename\u003e\u003cforename type=\"middle\"\u003eI\u003c/forename\u003e\u003csurname\u003eLi\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eBreast Cancer Res. Treat\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e127\u003c/biblScope\u003e\u003cbiblScope from=\"729\" to=\"738\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2011\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b3\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eProgress and opportunities in reducing racial disparities\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eC\u003c/forename\u003e\u003cforename type=\"middle\"\u003eE\u003c/forename\u003e\u003csurname\u003eDesantis\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cidno type=\"DOI\"\u003e10.3322/caac.21340(22February2016)\u003c/idno\u003e\u003cidno\u003edoi: 10.3322/ caac.21340\u003c/idno\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eCancer statistics for African Americans\u003c/title\u003e\u003cimprint\u003e\u003cdate type=\"published\" when=\"2016-02-22\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003cnote\u003eCA Cancer J Clin\u003c/note\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b4\"\u003e\u003cmonogr\u003e\u003ctitle level=\"m\" type=\"main\"\u003eProgress Since 2000: Workshop Summary\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eK\u003c/forename\u003e\u003cforename type=\"middle\"\u003eM\u003c/forename\u003e\u003csurname\u003eAnderson\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cptr target=\"http://www.nap.edu/read/13383/chapter\"/\u003e\u003cimprint\u003e\u003cdate type=\"published\" when=\"2000-04\"/\u003e\u003cpublisher\u003eThe National Acad. Press\u003c/publisher\u003e\u003cbiblScope unit=\"page\"\u003e14\u003c/biblScope\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b5\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eAmerican Society of Clinical Oncology policy statement: disparities in cancer care\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eE\u003c/forename\u003e\u003csurname\u003eGoss\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eJ. Clin. Oncol\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e27\u003c/biblScope\u003e\u003cbiblScope from=\"2881\" to=\"2885\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2009\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b6\"\u003e\u003cmonogr\u003e\u003ctitle level=\"m\" type=\"main\"\u003eThe European Organisation for Research and Treatment of Cancer. Aims \u0026amp; Mission\u003c/title\u003e\u003cptr target=\"http://www.eortc.org/\"/\u003e\u003cimprint\u003e\u003cdate type=\"published\" when=\"2016-04\"/\u003e\u003cbiblScope unit=\"page\"\u003e14\u003c/biblScope\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b7\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eA multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eS\u003c/forename\u003e\u003csurname\u003ePaik\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eN. Engl. J. Med\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e351\u003c/biblScope\u003e\u003cbiblScope from=\"2817\" to=\"2826\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2004\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b8\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eGene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eS\u003c/forename\u003e\u003csurname\u003ePaik\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eJ. Clin. Oncol\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope from=\"3726\" to=\"3734\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2006\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b9\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003ePrediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eM\u003c/forename\u003e\u003csurname\u003eDowsett\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eJ. Clin. Oncol\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e28\u003c/biblScope\u003e\u003cbiblScope from=\"1829\" to=\"1834\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2010\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b10\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003ePrognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptorpositive breast cancer on chemotherapy: a retrospective analysis of a randomised trial\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eK\u003c/forename\u003e\u003cforename type=\"middle\"\u003eS\u003c/forename\u003e\u003csurname\u003eAlbain\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eLancet Oncol\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e11\u003c/biblScope\u003e\u003cbiblScope from=\"55\" to=\"65\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2010\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b11\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eProspective validation of a 21-gene expression assay in breast cancer\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eJ\u003c/forename\u003e\u003cforename type=\"middle\"\u003eA\u003c/forename\u003e\u003csurname\u003eSparano\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eN. Engl. J. Med\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e373\u003c/biblScope\u003e\u003cdate type=\"published\" when=\"2005\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b12\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eReal-life analysis evaluating 2028 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene Recurrence Score result: 5-year KM estimate for breast cancer-specific survival with Recurrence Score results \u0026#x2264; 30 is 498%\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eS\u003c/forename\u003e\u003cforename type=\"middle\"\u003eM\u003c/forename\u003e\u003csurname\u003eStemmer\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cidno\u003eP5-08-02\u003c/idno\u003e\u003cptr target=\"https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2015-Abstracts.pdf?v=5\"/\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eSan Antonio Breast Cancer Symposium. Abstract\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"page\"\u003e14\u003c/biblScope\u003e\u003cdate type=\"published\" when=\"2015-04\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b13\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eWest German Study Group phase III PlanB trial: First prospective outcome data for the 21-gene Recurrence Score assay and concordance of prognostic markers by central and local pathology assessment\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eO\u003c/forename\u003e\u003csurname\u003eGluz\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cidno type=\"DOI\"\u003e10.1200/JCO.2015.63.5383\u003c/idno\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eJ Clin Oncol\u003c/title\u003e\u003cimprint\u003e\u003cdate type=\"published\" when=\"2016-02-29\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b14\"\u003e\u003canalytic\u003e\u003ctitle/\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eN\u003c/forename\u003e\u003csurname\u003eHowlader\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cptr target=\"http://seer.cancer.gov/csr/1975_2012\"/\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eCancer Statistics Review. National Cancer Institute\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"page\"\u003e14\u003c/biblScope\u003e\u003cdate type=\"published\" when=\"1975\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b15\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eA population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eL\u003c/forename\u003e\u003cforename type=\"middle\"\u003eA\u003c/forename\u003e\u003csurname\u003eHabel\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eBreast Cancer Res\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e8\u003c/biblScope\u003e\u003cbiblScope unit=\"page\"\u003e25\u003c/biblScope\u003e\u003cdate type=\"published\" when=\"2006\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b16\"\u003e\u003cmonogr\u003e\u003ctitle level=\"m\" type=\"main\"\u003eletrozole, anastrozole, or exemestane with or without chemotherapy in treating patients with invasive RxPONDER breast cancer\u003c/title\u003e\u003cptr target=\"https://clinicaltrials.gov/ct2/show/NCT01272037\"/\u003e\u003cimprint\u003e\u003cdate type=\"published\" when=\"2016-04\"/\u003e\u003cbiblScope unit=\"page\"\u003e14\u003c/biblScope\u003e\u003c/imprint\u003e\u003crespStmt\u003e\u003corgName\u003eNational Cancer Institute. Tamoxifen citrate\u003c/orgName\u003e\u003c/respStmt\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b17\"\u003e\u003cmonogr\u003e\u003ctitle level=\"m\"\u003eData on file\u003c/title\u003e\u003cimprint\u003e\u003cpublisher\u003eGenomic Health, Inc\u003c/publisher\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b18\"\u003e\u003cmonogr\u003e\u003ctitle level=\"m\" type=\"main\"\u003eEuropean Organisation for Research and Treatment of Cancer. MINDACT (Microarray In Node negative Disease may Avoid ChemoTherapy\u003c/title\u003e\u003cptr target=\"http://www.eortc.be/services/unit/mindact/documents/MINDACT_trial_outline.pdf\"/\u003e\u003cimprint\u003e\u003cdate type=\"published\" when=\"2016-04\"/\u003e\u003cbiblScope unit=\"page\"\u003e14\u003c/biblScope\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b19\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eDifferent patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eY\u003c/forename\u003e\u003cforename type=\"middle\"\u003eR\u003c/forename\u003e\u003csurname\u003eLiu\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eY\u003c/forename\u003e\u003cforename type=\"middle\"\u003eZ\u003c/forename\u003e\u003csurname\u003eJiang\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eK\u003c/forename\u003e\u003cforename type=\"middle\"\u003eD\u003c/forename\u003e\u003csurname\u003eYu\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eZ\u003c/forename\u003e\u003cforename type=\"middle\"\u003eM. ; W\u003c/forename\u003e\u003csurname\u003eShao\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"m\"\u003e22. van de Water\u003c/title\u003e\u003cimprint\u003e\u003cdate type=\"published\" when=\"2012\"/\u003e\u003cbiblScope unit=\"volume\"\u003e22\u003c/biblScope\u003e\u003cbiblScope from=\"590\" to=\"597\" unit=\"page\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003cnote\u003eJAMA\u003c/note\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b20\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eEffect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eR\u003c/forename\u003e\u003csurname\u003eYancik\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eJAMA\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e285\u003c/biblScope\u003e\u003cbiblScope from=\"885\" to=\"892\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2001\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b21\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eVariation in \u0026apos;standard care\u0026apos; for breast cancer across Europe: a EUROCARE-3 high resolution study\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eC\u003c/forename\u003e\u003csurname\u003eAllemani\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eEur. J. Cancer\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e46\u003c/biblScope\u003e\u003cbiblScope from=\"1528\" to=\"1536\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2010\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b22\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eBreast cancer treatment guidelines in older women\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eS\u003c/forename\u003e\u003cforename type=\"middle\"\u003eH\u003c/forename\u003e\u003csurname\u003eGiordano\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eG\u003c/forename\u003e\u003cforename type=\"middle\"\u003eN\u003c/forename\u003e\u003csurname\u003eHortobagyi\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eS\u003c/forename\u003e\u003cforename type=\"middle\"\u003eW\u003c/forename\u003e\u003csurname\u003eKau\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eR\u003c/forename\u003e\u003cforename type=\"middle\"\u003eL\u003c/forename\u003e\u003csurname\u003eTheriault\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eM\u003c/forename\u003e\u003cforename type=\"middle\"\u003eL\u003c/forename\u003e\u003csurname\u003eBondy\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eJ. Clin. Oncol\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e23\u003c/biblScope\u003e\u003cbiblScope from=\"783\" to=\"791\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2005\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b23\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eNational Comprehensive Cancer Network\u003c/title\u003e\u003cptr target=\"http://www.nccn.org/professionals/physician_gls/pdf/senior.pdf\"/\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eClinical Practice Guidelines in Oncology: Older Adult Oncology. Version\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e1\u003c/biblScope\u003e\u003cbiblScope unit=\"page\"\u003e14\u003c/biblScope\u003e\u003cdate type=\"published\" when=\"2016-04\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b24\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eclinical impact of risk classification by central/local grade or luminallike subtype vs. Oncotype DX: First prospective survival results from the WSG phase III planB trial\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eO\u003c/forename\u003e\u003csurname\u003eGluz\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eEur J Cancer\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e51\u003c/biblScope\u003e\u003cbiblScope unit=\"issue\"\u003eS311\u003c/biblScope\u003e\u003cdate type=\"published\" when=\"1937\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b25\"\u003e\u003cmonogr\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eO\u003c/forename\u003e\u003csurname\u003eGluz\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cptr target=\"http://www.poster-submission.com/SGBCC2015/visitors/search/\"/\u003e\u003ctitle level=\"m\"\u003eLuminal subtypes vs. early Ki-67 response and Oncotype DX in early breast cancer: WSG-ADAPT study. 14th St. Gallen International Breast Cancer Conference\u003c/title\u003e\u003cimprint\u003e\u003cdate type=\"published\" when=\"2015-04\"/\u003e\u003cbiblScope unit=\"page\"\u003e14\u003c/biblScope\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003cnote\u003eAbstract P231. Available at\u003c/note\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b26\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eGRACE principles: recognizing high-quality observational studies of comparative effectiveness\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eN\u003c/forename\u003e\u003cforename type=\"middle\"\u003eA\u003c/forename\u003e\u003csurname\u003eDreyer\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eAm. J. Manag. Care\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e16\u003c/biblScope\u003e\u003cbiblScope from=\"467\" to=\"471\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2010\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b27\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eComparison of SEER treatment data with Medicare claims\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eA\u003c/forename\u003e\u003cforename type=\"middle\"\u003eM\u003c/forename\u003e\u003csurname\u003eNoone\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cidno type=\"DOI\"\u003e10.1097/MLR.0000000000000073\u003c/idno\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eMed Care\u003c/title\u003e\u003cimprint\u003e\u003cdate type=\"published\" when=\"2014-03-15\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b28\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eEarly Breast Cancer Trialists\u0026apos; Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials\u003c/title\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eLancet\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e365\u003c/biblScope\u003e\u003cbiblScope from=\"1687\" to=\"1717\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2005\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b29\"\u003e\u003cmonogr\u003e\u003ctitle level=\"m\" type=\"main\"\u003eAmerican Joint Committee on Cancer\u003c/title\u003e\u003cptr target=\"https://cancerstaging.org/references-tools/quickreferences/Documents/BreastMedium.pdf\"/\u003e\u003cimprint\u003e\u003cdate type=\"published\" when=\"2016-04\"/\u003e\u003cpublisher\u003eSpringer-Verlag\u003c/publisher\u003e\u003cbiblScope unit=\"page\"\u003e14\u003c/biblScope\u003e\u003cpubPlace\u003eNew York\u003c/pubPlace\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003cnote\u003eBreast Cancer Staging: 7th edn\u003c/note\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b30\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eHER2 concordance between central laboratory immunohistochemistry and quantitative reverse transcription polymerase chain reaction in Intergroup Trial E2197\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eF\u003c/forename\u003e\u003cforename type=\"middle\"\u003eL\u003c/forename\u003e\u003csurname\u003eBaehner\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eJ Clin Oncol\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e26\u003c/biblScope\u003e\u003cbiblScope unit=\"page\"\u003e22009\u003c/biblScope\u003e\u003cdate type=\"published\" when=\"2008\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b31\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eComparison of HER2 testing by IHC/FISH and RT-PCR in estrogen receptor negative or borderline patients with early stage breast cancer\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eB\u003c/forename\u003e\u003csurname\u003eSingh\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eMod Pathol\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e26\u003c/biblScope\u003e\u003cbiblScope unit=\"issue\"\u003e282\u003c/biblScope\u003e\u003cdate type=\"published\" when=\"2013\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b32\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eHuman epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eF\u003c/forename\u003e\u003cforename type=\"middle\"\u003eL\u003c/forename\u003e\u003csurname\u003eBaehner\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eJ Clin Oncol\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e28\u003c/biblScope\u003e\u003cbiblScope from=\"4300\" to=\"4306\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2010\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b33\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eImproved estimates of cancer-specific survival rates from population-based data\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eN\u003c/forename\u003e\u003csurname\u003eHowlader\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eJ. Natl. Cancer Inst\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e102\u003c/biblScope\u003e\u003cbiblScope from=\"1584\" to=\"1598\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2010\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b34\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eImpact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eR\u003c/forename\u003e\u003csurname\u003eOratz\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eD\u003c/forename\u003e\u003csurname\u003ePaul\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eA\u003c/forename\u003e\u003cforename type=\"middle\"\u003eL\u003c/forename\u003e\u003csurname\u003eCohn\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eS\u003c/forename\u003e\u003cforename type=\"middle\"\u003eM\u003c/forename\u003e\u003csurname\u003eSedlacek\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eJ. Oncol. Pract\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e3\u003c/biblScope\u003e\u003cbiblScope from=\"182\" to=\"186\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2007\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b35\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eProspective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eS\u003c/forename\u003e\u003cforename type=\"middle\"\u003eS\u003c/forename\u003e\u003csurname\u003eLo\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eJ. Clin. Oncol\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e28\u003c/biblScope\u003e\u003cbiblScope from=\"1671\" to=\"1676\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2010\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b36\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003ehe effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eJ\u003c/forename\u003e\u003cforename type=\"middle\"\u003eE\u003c/forename\u003e\u003csurname\u003eJoh\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eOncologist\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e16\u003c/biblScope\u003e\u003cbiblScope from=\"1520\" to=\"1526\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2011\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b37\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eThe effects of Oncotype DX Recurrence Scores on chemotherapy utilization in a multi-institutional breast cancer cohort\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eF\u003c/forename\u003e\u003cforename type=\"middle\"\u003eO\u003c/forename\u003e\u003csurname\u003eAdemuyiwa\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eBreast Cancer Res. Treat\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e126\u003c/biblScope\u003e\u003cbiblScope from=\"797\" to=\"802\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2011\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b38\"\u003e\u003canalytic\u003e\u003ctitle level=\"a\" type=\"main\"\u003eUsing a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data\u003c/title\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eM\u003c/forename\u003e\u003csurname\u003eYu\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eZ\u003c/forename\u003e\u003csurname\u003eTatalovich\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eJ\u003c/forename\u003e\u003cforename type=\"middle\"\u003eT\u003c/forename\u003e\u003csurname\u003eGibson\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003cauthor\u003e\u003cpersName\u003e\u003cforename type=\"first\"\u003eK\u003c/forename\u003e\u003cforename type=\"middle\"\u003eA\u003c/forename\u003e\u003csurname\u003eCronin\u003c/surname\u003e\u003c/persName\u003e\u003c/author\u003e\u003c/analytic\u003e\u003cmonogr\u003e\u003ctitle level=\"j\"\u003eCancer Causes Control\u003c/title\u003e\u003cimprint\u003e\u003cbiblScope unit=\"volume\"\u003e25\u003c/biblScope\u003e\u003cbiblScope from=\"81\" to=\"92\" unit=\"page\"/\u003e\u003cdate type=\"published\" when=\"2014\"/\u003e\u003c/imprint\u003e\u003c/monogr\u003e\u003c/biblStruct\u003e\u003cbiblStruct xml:id=\"b39\"\u003e\u003cmonogr\u003e\u003ctitle level=\"m\" type=\"main\"\u003eThe images or other third party material in this article are included in the article\u0026apos;s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material\u003c/title\u003e\u003cptr target=\"http://www.nature.com/npjbcancer\"/\u003e\u003cimprint/\u003e\u003c/monogr\u003e\u003cnote\u003eThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/ accompanies the paper on the npj Breast Cancer website\u003c/note\u003e\u003c/biblStruct\u003e\u003c/listBibl\u003e\u003c/div\u003e\u003c/back\u003e\u003c/text\u003e\u003c/TEI\u003e","updated_at":{"$date":"2020-03-25T05:46:06.588Z"},"__v":0}
